Desoximetasone

Relieves inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. ANDA 209973, held by The J Molner. Desoximetasone.

As of Nov 15, 2026, ANDA 209973 (Desoximetasone), held by The J Molner, was first approved by FDA on Oct 23, 2018, with 1 approved supplement and 0 published complete response letters.

First approved: Oct 23, 2018
Review: Standard
Supplements approved: 1
Complete response letters: 0

What It's For

From the FDA-approved label (Indications and Usage)

INDICATIONS AND USAGE Desoximetasone Ointment USP, 0.05% is indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.

Full prescribing information on DailyMed ↗

Approvals and New Uses

The original application and every efficacy supplement, newest first; all 2 submissions below

Date	Submission	Status	Documents
Oct 23, 2018	Original application	Approved	None posted

Products

1 strengths and forms

Product	Active ingredient	Marketing
Desoximetasone0.05% · ointment;topical	Desoximetasone	Rx

All 2 submissions, including labeling and manufacturing supplements


Mar 28, 2025	Supplement 4Manufacturing	Approved	None posted
Oct 23, 2018	Original application	Approved	None posted

Identifiers

Application: ANDA 209973
Drugs@FDA: Overview at FDA
Company: J. Molner

Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters